Association between use of acid-suppressive drugs and risk of gastric cancer: A nested case-control study

Drug Safety

Volumn 31, Issue 8, 2008, Pages 675-684

  Tamim, Hani ^a   Duranceau, André ^a   Chen, Long Qi ^a   LeLorier, Jacques ^a  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Gastric cancer, drug induced; Histamine H2 receptor antagonists, adverse reactions; Proton pump inhibitors, adverse reactions

Indexed keywords

HISTAMINE H2 RECEPTOR ANTAGONIST; PROTON PUMP INHIBITOR;

ADULT; AGED; ARTICLE; CANCER EPIDEMIOLOGY; CANCER RISK; CANCER STATISTICS; CARDIA CARCINOMA; CASE CONTROL STUDY; CONTROLLED STUDY; DRUG USE; FEMALE; GASTROESOPHAGEAL REFLUX; HELICOBACTER INFECTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; STOMACH ADENOCARCINOMA; STOMACH CANCER; TREND STUDY;

AGED; AGED, 80 AND OVER; ANTI-ULCER AGENTS; CASE-CONTROL STUDIES; FEMALE; GASTRIC ACID; HISTAMINE H2 ANTAGONISTS; HUMANS; MALE; ODDS RATIO; PROTON PUMP INHIBITORS; QUEBEC; RISK; STOMACH NEOPLASMS; TIME FACTORS;

EID: 47649114119     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200831080-00004     Document Type: Article

References (30)

1. Roder D. The epidemiology of gastric cancer. Gastric Cancer 2002; 5 (1): 5-11
2. Jemal A, Murray T, Samuels A, et al. Cancer statistics, 2003. CA Cancer J Clin 2003; 53: 5-26
3. Chow W, Finkle W, McLaughlin J, et al. The relation of gastroesophageal reflux disease and its treatment to adenocarcinomas of the esophagus and gastric cardia. JAMA 1995; 274 (6): 474-7
4. Lagergren J, Bergstrom R, Lindgren A, et al. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999; 340 (11): 825-31
5. Engel L, Chow W, Vaughan T, et al. Population attributable risks of esophageal and gastric cancers. J Natl Cancer Inst 2003; 95: 1404-13
6. Welage LS, Berardi RR. Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases. J Am Pharm Assoc 2000; 40: 52-62
7. Farrow D, Vaughan T, Sweeney C, et al. Gastroesophageal reflux disease, use of H2 receptor antagonists, and risk of esophageal and gastric cancer. Cancer Causes Control 2000; 11: 231-8
8. Enzinger P, Mayer R. Esophageal Cancer. N Engl J Med 2003; 349: 2241-52
9. Chang J, Katzka D. Gastroesophageal reflux diseases, Barrett esophagus, and esophageal adenocarcinoma. Arch Intern Med 2004; 164: 1482-8
10. Garcia Rodriquez LA, Lagergren J, Lindblad M. Gastric acid suppression and risk of oesophageal and gastric adenocarcinoma: a nested case control study in the UK. Gut 2006; 55 (11): 1538-44
11. Klinkenberg-Knol EC, Nelis F, Dent J, et al. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology 2000; 118: 661-9
12. Uemura N, Okamoto S, Yamamoto S. H. pylori infection and the development of gastric cancer. Keio J Med 2002; 51: 63-8
13. Carter M, Katz DL, Haque S, et al. Does acid suppression by antacids and H2 receptor antagonists increase the incidence of atrophic gastritis in patients with or without H. pylori gastritis. J Clin Gastroenterol 1999; 29: 183-7
14. Tamblyn R, Lavoie G, Petrella L, et al. The use of prescription claims databases in pharmaco-epidemiological research: the accuracy and comprehensiveness of the prescription claims database in Quebec. J Clin Epidemiol 1995; 48: 999-1009
15. Régie de l'Assurance Maladie du Québec. Statistiques annuelles 2003. Quebec City: Quebec Government, 2003
16. WHO. International classification of diseases. 9th rev (ICD-9). Geneva: WHO, 1977
17. Tamim H, Tahami A, LeLorier J. Application of lag-time into exposure definitions to control protopathic bias. Pharmacoepidemiol Drug Saf 2007; 16 (3): 250-8
18. Guidelines for ATC classification and DDD assignment. Oslo: WHO Collaborating Centre for Drug Statistics Methodology, 2001 [online]. Available from URL: http://www.whocc.no/atcddd [Accessed 2008 May 1]
19. Hillman L, Chiragakis L, Shadbolt B, et al. Proton pump inhibitor therapy and the development of dysplasia in patients with Barrett's oesophagus. Med J Aust 2004; 180: 387-91
20. El-Serag H, Aguirre T, Davis S, et al. Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett's esophagus. Am J Gastroenterol 2004; 99: 1877-83
21. Corley D, Kubo A. Influence of site classification on cancer incidence rates: an analysis of gastric cardia carcinomas. J Natl Cancer Inst 2004; 96 (18): 1383-71
22. Vanderhoff B, Tahboub R. Proton pump inhibitors: an update. Am Fam Physician 2002; 66 (2): 273-80
23. Alberts SR, Cervantes A, van de Velde CJ. Gastric cancer: epidemiology, pathology and treatment. Ann Oncol 2003; 14 Suppl. 2: 31-6
24. Bradford-Hill A. The environment and disease: association or causation? Proc R Soc Med 1965; 58: 295-30
25. Hansson LE, Nyren O, Hsing AW, et al. The risk of stomach cancer in patients with gastric or duodenal ulcer disease. N Engl J Med 1996; 335: 242-9
26. La Vecchia C, Braga C, Negri E, et al. Risk of stomach cancer in patients with gastric or duodenal ulcer. Eur J Cancer Prev 1997; 6: 20-3
27. Blot WJ, Devesa SS, Kneller RW, et al. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 1991; 265 (10): 1287-9
28. Powell J, McConkey CC. The rising trend in oesophageal adenocarcinoma and gastric cardia. Eur J Cancer Prev 1992; 1 (3): 265-9
29. Morales TG. Adenocarcinoma of the gastric cardia. Dig Dis 1997; 15 (6): 346-56
30. Roder D. The epidemiology of gastric cancer. Gastric Cancer 2002; 5 (1): 5-11